Heart Research Institute Charles Perkins Centre University of Sydney Australia.
The George Institute for Global Health University of New South Wales Sydney Australia.
J Am Heart Assoc. 2020 Sep 15;9(18):e017080. doi: 10.1161/JAHA.120.017080. Epub 2020 Aug 31.
BACKGROUND Internationally, most atrial fibrillation (AF) management guidelines recommend opportunistic screening for AF in people ≥65 years of age and oral anticoagulant treatment for those at high stroke risk (CHA₂DS₂-VA≥2). However, gaps remain in screening and treatment. METHODS AND RESULTS General practitioners/nurses at practices in rural Australia (n=8) screened eligible patients (≥65 years of age without AF) using a smartphone ECG during practice visits. eHealth tools included electronic prompts, guideline-based electronic decision support, and regular data reports. Clinical audit tools extracted de-identified data. Results were compared with an earlier study in metropolitan practices (n=8) and nonrandomized control practices (n=69). Cost-effectiveness analysis compared population-based screening with no screening and included screening, treatment, and hospitalization costs for stroke and serious bleeding events. Patients (n=3103, 34%) were screened (mean age, 75.1±6.8 years; 47% men) and 36 (1.2%) new AF cases were confirmed (mean age, 77.0 years; 64% men; mean CHA₂DS₂-VA, 3.2). Oral anticoagulant treatment rates for patients with CHA₂DS₂-VA≥2 were 82% (screen detected) versus 74% (preexisting AF)(=NS), similar to metropolitan and nonrandomized control practices. The incremental cost-effectiveness ratio for population-based screening was AU$16 578 per quality-adjusted life year gained and AU$84 383 per stroke prevented compared with no screening. National implementation would prevent 147 strokes per year. Increasing the proportion screened to 75% would prevent 177 additional strokes per year. CONCLUSIONS An AF screening program in rural practices, supported by eHealth tools, screened 34% of eligible patients and was cost-effective. Oral anticoagulant treatment rates were relatively high at baseline, trending upward during the study. Increasing the proportion screened would prevent many more strokes with minimal incremental cost-effectiveness ratio change. eHealth tools, including data reports, may be a valuable addition to future programs. REGISTRATION URL: https://www.anzctr.org.au. Unique identifier: ACTRN12618000004268.
在国际上,大多数房颤(AF)管理指南建议在≥65 岁的人群中进行机会性筛查,并对高卒中风险人群(CHA₂DS₂-VA≥2)进行口服抗凝治疗。然而,在筛查和治疗方面仍存在差距。
澳大利亚农村实践中的全科医生/护士(n=8)在就诊期间使用智能手机心电图对符合条件的患者(≥65 岁且无房颤)进行筛查。电子健康工具包括电子提示、基于指南的电子决策支持和定期数据报告。临床审核工具提取了去识别数据。结果与大都市实践(n=8)和非随机对照实践(n=69)的早期研究进行了比较。成本效益分析比较了基于人群的筛查与不筛查,并包括卒中和严重出血事件的筛查、治疗和住院费用。对 3103 名患者(34%)进行了筛查(平均年龄 75.1±6.8 岁;47%为男性),并确诊了 36 例(1.2%)新的房颤病例(平均年龄 77.0 岁;64%为男性;平均 CHA₂DS₂-VA 为 3.2)。CHA₂DS₂-VA≥2 的患者口服抗凝治疗率为 82%(筛查发现)与 74%(既往房颤)(=NS),与大都市和非随机对照实践相似。与不筛查相比,基于人群的筛查的增量成本效益比为每获得 1 个质量调整生命年增加 16578 澳元,每预防 1 例卒中增加 84383 澳元。全国实施每年可预防 147 例卒中。将筛查比例提高到 75%,每年可额外预防 177 例卒中。
在农村实践中,一项由电子健康工具支持的房颤筛查计划筛查了 34%的合格患者,具有成本效益。在研究期间,口服抗凝治疗率基线较高,呈上升趋势。增加筛查比例将以最小的增量成本效益比变化预防更多的卒中。电子健康工具,包括数据报告,可能是未来计划的有价值的补充。